Saxagliptin Hydrochloride Patent Expiration
Saxagliptin Hydrochloride is used for managing type II diabetes. It was first introduced by Astrazeneca Ab
Saxagliptin Hydrochloride Patents
Given below is the list of patents protecting Saxagliptin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Onglyza | US7951400 | Coated tablet formulation and method | Nov 30, 2028 | Astrazeneca Ab |
| Onglyza | USRE44186 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul 31, 2023
(Expired) | Astrazeneca Ab |
| Onglyza | US6395767 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Feb 16, 2021
(Expired) | Astrazeneca Ab |
Saxagliptin Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List